Teva Pharmaceuticals (NYSE: TEVA) is scheduled to report second quarter 2019 earnings results on Wednesday, August 7, before market open. Analysts expect to report earnings of $0.57 per share on revenue of $4.25 billion.
Teva has been struggling with tough competition and pricing challenges in the generics market and this is expected to continue in the second quarter. Revenue declines in Copaxone as well as other key brands is also expected to hurt the top line numbers. Teva is also likely to see pressure in Europe due to discontinued business operations.
However, the company is expected to benefit from the sales of new products which are likely to partially offset the weakness in other areas. Cost-saving efforts are expected to help margins during the quarter. Updates on the company’s new product launches and approvals for new indications are areas to keep an eye out for.
In the first quarter of 2019, Teva beat earnings estimates but revenues missed expectations. Revenues fell 15% to $4.3 billion while adjusted EPS dropped 36% to $0.60. Revenues decreased in all geographic regions. Generic products and Copaxone saw sales declines across all markets.
For the full year of 2019, Teva has guided for revenues in the range of $17-17.4 billion and adjusted EPS in the range of $2.20-2.50.
Teva’s shares have dropped 50% year-to-date and 17% over the past one month. The majority of analysts have rated the stock Hold and it has a price target of $10.75.
Aurora Cannabis, Inc. (NYSE: ACB) reported a wider loss for the fourth quarter of 2020, hurt by a 5% decrease in revenues. The company’s stock fell sharply during Tuesday’s after-hours
Stitch Fix (NASDAQ: SFIX) reported fourth-quarter 2020 financial results after the closing bell on Tuesday. The company reported an 11% increase in Q4 revenues to $443.4 million, beating Wall Street
Nike Inc.'s (NYSE: NKE) profit and revenue in the first quarter of fiscal 2021 surpassed the market's estimates and sent the NKE stock up by about 7% in the extended